ESR1 and neoplasm: When there is a disagreement in ER status between IHC and RNA‐Seq in a patient where both data types are available, it could indicate that more careful investigation is needed—potentially, there might be tumours classified as ER‐negative in patients that could benefit from endocrine therapy.